UVA engineering polymer scientist wins American Physical Society’s John H. Dillon Medal
Grant and Award Announcement
Updates every hour. Last Updated: 23-Dec-2025 00:11 ET (23-Dec-2025 05:11 GMT/UTC)
Robot-guided neurosurgery in patients with epilepsy involves accurately mapping the skull to identify the entry points and target areas. A recent study compared the clinical utility of a contactless optical method with the conventional method, which requires repeated contacts. The study demonstrates that optical tracking is accurate, less time-consuming, and easily learned by new users. These findings pave the way for faster and more error-free surgical interventions for epilepsy.
The authors have proposed the Microbiota-derived metabolites–epigenetics (MDME) axis, a conceptual framework explaining how microbial metabolites function as a critical link between the environment and host health. These metabolites directly instruct the host's epigenome, reprogramming gene expression and regulating host health and diseases. Diverse categories of metabolites contributing to host health via different epigenetic mechanisms are comprehensively discussed. This perspective moves beyond simple associations to provide a predictive model for how our lifestyle, mediated by our microbiome, shapes our health and disease risk, opening new avenues for mechanistic and therapeutic studies.
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 “bird flu”. The study, published today in the journal Nature Communications, [DK1] highlights the potential of mucosal immunization strategies--where vaccines are sprayed into the nostrils--to prime immune defenses against diverse influenza strains.
Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so profoundly that it can distort a person’s sense of reality. Now—just over a year after the first new schizophrenia drug in half a century was approved—a study in Nature Mental Health looks at how patients respond to it, offering early clues for more personalized treatment.